Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.33 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2546940 | 1.00 | NPC1 (0.47) | NPC1L3MBTL1PARP1LMNATRPM8 | |
| SCHEMBL1630772 | 0.89 | NPC1 (0.54) | NPC1L3MBTL1PARP1LMNATRPM8 | |
| SCHEMBL1022195 | 0.89 | NPC1 (0.54) | NPC1L3MBTL1PARP1LMNATRPM8 | |
| SCHEMBL1395649 | 0.89 | NPC1 (0.54) | NPC1L3MBTL1PARP1LMNATRPM8 | |
| SCHEMBL1903390 | 0.80 | NPC1 (0.52) | NPC1L3MBTL1PARP1LMNATRPM8 | |
| SCHEMBL1395640 | 0.80 | NPC1 (0.52) | NPC1L3MBTL1PARP1LMNATRPM8 | |
| SCHEMBL4016170 | 0.80 | NPC1 (0.52) | NPC1L3MBTL1PARP1LMNATRPM8 | |
| SCHEMBL3094338 | 0.78 | NPC1 (0.46) | NPC1L3MBTL1PARP1LMNATRPM8 | |
| SCHEMBL3094329 | 0.78 | NPC1 (0.46) | NPC1L3MBTL1PARP1LMNATRPM8 | |
| SCHEMBL1831175 | 0.78 | NPC1 (0.46) | NPC1L3MBTL1PARP1LMNATRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263873-A1 | Enantioselective Synthesis of y-amino-alpha beta-unsaturated carboxylic acid derivatives | NOVARTIS AG (CH) | 2011-10-27 | — | — | US | disclosed |
| EP-1449835-A2 | Alpha-substituted pyrimidine-thioalkyl and alkylether compounds | PHARMACIA & UPJOHN COMPANY (US) | 2004-08-25 | — | — | EP | disclosed |
| US-6043248-A | VIRICIDES FOR TREATING AN INDIVIDUAL INFECTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS | PHARMACIA & UPJOHN COMPANY (US) | 2000-03-28 | — | — | US | disclosed |
| EP-0824524-A1 | ALPHA-SUBSTITUTED PYRIMIDINE-THIOALKYL AND ALKYLETHER COMPOUNDS AS INHIBITORS OF VIRAL REVERSE TRANSCRIPTASE | PHARMACIA & UPJOHN COMPANY (US) | 1998-02-25 | — | — | EP | disclosed |
| WO-1996035678-A1 | ALPHA-SUBSTITUTED PYRIMIDINE-THIOALKYL AND ALKYLETHER COMPOUNDS AS INHIBITORS OF VIRAL REVERSE TRANSCRIPTASE | PHARMACIA & UPJOHN COMPANY (US) | 1996-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263873-A1 | Enantioselective Synthesis of y-amino-alpha beta-unsaturated carboxylic acid derivatives | BCAT1, BCAT2, AADAT | NPC1 3393/4885L3MBTL1 3545/4885PARP1 1496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.